Stock data
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX) reported revenue of US$14.56M and net income of -US$63.53M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$14.56M | — | -US$36.62M | -US$63.53M | — |
| 2024 | US$9.50M | — | -US$21.48M | -US$18.61M | — |
| 2023 | US$8.95M | US$8.27M | -US$24.73M | -US$21.49M | — |
| 2022 | US$14.70M | US$13.97M | -US$22.52M | -US$26.27M | — |
| 2021 | US$4.34M | US$2.92M | -US$49.21M | -US$43.02M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$1.07M | US$1.48M | — |
| 2026-03-31 | US$1.73M | -US$4.81M | — |
| 2025-12-31 | US$6.61M | US$0.85M | — |
| 2025-09-30 | US$3.68M | -US$29.78M | — |
| 2025-06-30 | US$2.77M | -US$30.46M | — |
| 2025-03-31 | US$1.50M | -US$4.14M | — |
| 2024-12-31 | US$2.87M | -US$3.27M | — |
| 2024-09-30 | US$3.78M | -US$3.03M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.